证券研究报告——晨会聚焦 2025 年 8 月 26 日 | 8 月金股组合 | | | --- | --- | | 股票代码 | 股票名称 | | 002352.SZ | 顺丰控股 | | 002648.SZ | 卫星化学 | | 688019.SH | 安集科技 | | 600276.SH | 恒瑞医药 | | 688198.SH | 佰仁医疗 | | 600861.SH | 北京人力 | | 300395.SZ | 菲利华 | | 601138.SH | 工业富联 | | 002938.SZ | 鹏鼎控股 | | 688615.SH | 合合信息 | 中银晨会聚焦-20250826 【医药生物】华东医药*刘恩阳。公司公布 25 年中报，上半年公司实现总营 业收入 216.75 亿元，同比增长 3.39%；归母净利润为 18.15 亿元，同比增长 7.01%；扣非归母净利润为 17.62 亿元，同比增长 8.40%。公司拟向全体股东 每 10 股派发现金红利 3.50 元（含税），送红股 0 股（含税），不以公积金 转增股本。公司业务稳健增长，创新产品逐步进入收获期，我们看好公司的 长期发展。 | 行业表 ...

买入 原评级：买入 市场价格:人民币 45.71 板块评级:强于大市 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 37.7 2.9 8.6 51.5 相对深圳成指 19.6 (5.4) (7.2) 6.6 发行股数 (百万) 1,754.08 流通股 (百万) 1,751.94 总市值 (人民币 百万) 80,178.86 3 个月日均交易额 (人民币 百万) 636.19 主要股东持股比例 (8%) 5% 19% 32% 45% 59% Aug-24 Sep-24 Oct-24 Nov-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 华东医药 深圳成指 资料来源：公司公告， Wind ，中银证券 以 2025 年 8 月 21 日收市价为标准 医药生物 | 证券研究报告 — 业绩评论 2025 年 8 月 25 日 000963.SZ 相关研究报告 《华东医药》20250424 《华东医药》20241028 《华东医药》20240816 中银国际证券股份有限公司 具备证券投资咨询业务资格 医药生物：化学制药 证券分 ...

Core Viewpoint - Huadong Medicine reported a steady growth in its financial performance for the first half of 2025, with revenue reaching 21.675 billion yuan, a year-on-year increase of 3.39%, and a net profit of 1.815 billion yuan, up 7.01% [1] Financial Performance - The company achieved a total revenue of 21.675 billion yuan in the first half of 2025, reflecting a 3.39% increase year-on-year [1] - The net profit attributable to shareholders was 1.815 billion yuan, marking a 7.01% growth, while the net profit excluding non-recurring items was 1.762 billion yuan, up 8.40% [1] - A mid-year dividend of 614 million yuan is proposed, representing 33.83% of the net profit for the first half of 2025 [1] Business Growth and Product Commercialization - Huadong Medicine's core subsidiary, Zhongmei Huadong, reported a revenue of 7.317 billion yuan, a 9.24% increase, and a net profit of 1.580 billion yuan, up 14.09% [2] - The innovative product sales and agency service revenue reached 1.084 billion yuan, with a significant growth of 59% [2] - The CAR-T product, Zekai Ze, has expanded its market coverage, with over 20 provinces certified and more than 100 insurance projects included for reimbursement [2] R&D and Innovation - The company invested 1.484 billion yuan in R&D, a 33.75% increase, with direct R&D spending at 1.174 billion yuan, up 54.21% [6] - Huadong Medicine is advancing over 80 innovative drug pipelines, focusing on oncology, endocrinology, and autoimmune diseases [6][7] - The ADC product pipeline is progressing well, with several candidates in clinical trials and receiving orphan drug designation from the FDA [8] Industrial Microbiology and Aesthetic Medicine - The industrial microbiology segment achieved sales of 368 million yuan, a 29% increase, with significant growth in various sub-segments [10] - The aesthetic medicine division has launched multiple products, with strong market reception and ongoing registration efforts for new products [11][12] - The company aims to enhance its global presence and continue driving innovation in both pharmaceutical and aesthetic sectors [12]